Related Experiment Videos
Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population
Filipa Aguiar1, Gabriela Fernandes2, Henrique Queiroga2
1Pneumology Department, Hospital de Braga, Portugal.
Background:
Patients with activating somatic mutations in the Epidermal Growth Factor Receptor (EGFR) have better clinical outcomes when treated with Tyrosine Kinase Inhibitors (TKI) over chemotherapy. However, the impact of the use of TKIs on overall survival outside clinical trials is not well established.
Objective:
To characterize and analyze the overall survival of a Caucasian population with NSCLC and EGFR mutations.
Methods:
A retrospective cohort analysis of patients with NSCLC screened for EGFR mutations (exons 18-21) between October 2009 and July 2013 was conducted. Clinical and pathological characteristics, mutational EGFR status, treatment and overall survival were evaluated.
Results:
From the 285 patients which performed screening for EGFR mutations, 54 (18.9%) had mutations, 25 (46.3%) of which in exon 19 and 20 of which (37.0%) in exon 21. The occurrence of mutations was associated with female sex and non-smoking habits (both, P<.001). The median survival of the global population was 12.0 months, with a better overall survival in mutated than non-mutated patients (20.0 vs 11.0 months, respectively; P=.007).
Conclusion:
These data contribute for a better knowledge of our lung cancer population concerning the mutational status and clinical outcomes, confirming a better overall survival for the patients with EGFR TKI sensible mutations.
Insights
Patients with Epidermal Growth Factor Receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) show improved survival when treated with Tyrosine Kinase Inhibitors (TKIs). This study confirms better overall survival for EGFR-mutated NSCLC patients outside clinical trials.
Area of Science:
- Oncology
- Genetics
- Clinical Research
Background:
- Activating somatic mutations in Epidermal Growth Factor Receptor (EGFR) predict better outcomes with Tyrosine Kinase Inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
- The real-world impact of TKIs on overall survival for NSCLC patients with EGFR mutations remains under-investigated.
Purpose of the Study:
- To analyze the overall survival of Caucasian NSCLC patients with EGFR mutations.
- To characterize the clinical and mutational profile of this patient cohort.
Main Methods:
- Retrospective cohort analysis of 285 NSCLC patients screened for EGFR mutations (exons 18-21) from October 2009 to July 2013.
- Evaluation of clinical, pathological, EGFR mutational status, treatment, and overall survival data.
Main Results:
- EGFR mutations were identified in 18.9% of patients, predominantly in exon 19 and 21.
- Mutations were associated with female sex and non-smoking status (P<.001).
- Median overall survival was significantly better for patients with EGFR mutations compared to those without (20.0 vs 11.0 months, P=.007).
Conclusions:
- This study enhances understanding of the mutational landscape and clinical outcomes in a Caucasian NSCLC population.
- Confirms superior overall survival for NSCLC patients harboring EGFR TKI-sensitizing mutations.